Research programme: antibacterials - Pylum Biosciences
Alternative Names: Acinetobacter infection therapy - Pylum Biosciences; Avidocin therapeutics; Avidocin™ proteins; Clostridium difficile infection therapy - Pylum Biosciences; Escherichia coli infection therapy - Pylum Biosciences; Pseudomonas aeruginosa infection therapy - Pylum Biosciences; Yersinia pestis therapy - Pylum BiosciencesLatest Information Update: 28 Feb 2022
Price :
$50 *
At a glance
- Originator AvidBiotics Corp.
- Class Bacteriocins; Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acinetobacter infections; Clostridium infections; Escherichia coli infections; Prevotella infections; Pseudomonal infections; Shiga-toxigenic Escherichia coli infections; Yersinia infections
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for research development in Prevotella-infections in USA
- 28 Nov 2019 No recent reports of development identified for preclinical development in Clostridium-infections in USA
- 28 Nov 2019 No recent reports of development identified for research development in Acinetobacter-infections in USA